

AGM Results

Melbourne, Australia; 20 November 2020: In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act, Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) advises that details of the resolutions and the proxies and votes received in respect of each resolution at its AGM today are set out in the attached proxy and voting summary.

About Starpharma

Starpharma Holdings Limited (ASX: SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma's underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses. Starpharma has two core development programs: VivaGel® portfolio and DEP® drug delivery with the Company developing several products internally and others via commercial partnerships.

VivaGel®: Starpharma's women's health product - VivaGel® BV is based on SPL7013, astodimer sodium, a proprietary dendrimer. VivaGel® BV for bacterial vaginosis (BV), is available for sale under the brand names Betafem® BV Gel (UK), Betadine BV™ (Europe), Betadine™ BV Gel (Asia) and Fleurstat BVgel (Australia and New Zealand) and a new drug application has been submitted to the US FDA. Starpharma has licensed the sales and marketing of VivaGel® BV to ITF Pharma for the US; Mundipharma for Europe, Russia, CIS, Asia, the Middle East, Africa and Latin America; and to Aspen Pharmacare for Australia and New Zealand. Starpharma also has licence agreements to market the VivaGel® condom (an antiviral condom which includes VivaGel® in the lubricant) in several regions, including Australia, Europe, Canada, China and Japan (Okamoto). The VivaGel® condom has been launched in Japan under Okamoto's 003 brand, and in Australia and Canada under the LifeStyles Dual Protect® brand. The VivaGel® condom is approved in Europe.

DEP® - Dendrimer Enhanced Product®: Starpharma's DEP® drug delivery platform has demonstrated reproducible preclinical benefits across multiple internal and partnered DEP® programs, including improved efficacy, safety and survival. Starpharma has three internal DEP® products – DEP® docetaxel, DEP® cabazitaxel and DEP® irinotecan - in clinical development in patients with solid tumours. Starpharma's partnered DEP® programs include a multiproduct DEP® licence with AstraZeneca, which involves the development and commercialisation of two novel oncology compounds, with potential to add more. In June 2019 Starpharma signed a Development and Option agreement with AstraZeneca for a DEP® version of one of AstraZeneca's major marketed oncology medicines.

Starpharma.com | [Twitter](https://twitter.com/starpharma) | [Linkedln](https://www.linkedin.com/company/starpharma)

Media:

WE Communications
Rebecca Wilson
Mob: +61 417 382 391
rwilson@we-worldwide.com
Arthur Chan
+61 2 9237 2805
arthurc@we-worldwide.com

Starpharma Holdings Limited

Dr Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford Vic 3067

Disclosure

This ASX Announcement was authorised for release by the Company Secretary, Mr Nigel Baade.

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

STARPHARMA HOLDINGS LIMITED
2020 Annual General Meeting
Friday, 20 November 2020
Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of Remuneration Report	Ordinary	181,056,076 81.32%	39,314,516 17.65%	2,313,223 1.03%	5,309,202	184,042,276 82.28%	39,644,996 17.72%	5,424,202	Carried
2 Re-election of Mr Robert B Thomas AO	Ordinary	217,433,752 94.99%	9,150,882 4.00%	2,310,223 1.01%	5,648,066	220,556,952 95.91%	9,411,362 4.09%	5,693,066	Carried
3 Re-election of Mr David McIntyre	Ordinary	225,211,913 98.27%	1,654,814 0.72%	2,320,223 1.01%	5,355,973	228,590,623 99.27%	1,669,784 0.73%	5,400,973	Carried
4 Approval of Starpharma Employee Performance Rights Plan	Ordinary	210,916,372 94.14%	10,939,054 4.88%	2,195,763 0.98%	5,466,594	213,985,112 95.05%	11,139,534 4.95%	5,511,594	Carried
5 Approval of issue of Performance Rights to Dr Jacinth Fairley – In lieu of FY20 cash bonus	Ordinary	181,059,409 80.95%	40,289,663 18.01%	2,324,223 1.04%	5,844,488	184,216,609 81.97%	40,530,143 18.03%	5,889,488	Carried
6 Approval of issue of Performance Rights to Dr Jacinth Fairley – Prospective performance rights	Ordinary	209,459,841 93.44%	12,392,215 5.53%	2,304,223 1.03%	5,361,504	212,527,041 94.39%	12,632,695 5.61%	5,476,504	Carried
7 Renewal of Proportional Takeover provisions	Ordinary	220,398,887 97.52%	3,222,688 1.43%	2,365,223 1.05%	8,556,125	223,726,387 98.56%	3,263,868 1.44%	8,671,125	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.